Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial

Eur J Heart Fail. 2020 Mar;22(3):559-561. doi: 10.1002/ejhf.1723. Epub 2020 Jan 7.

Johannes Petutschnigg^{1

2}, João Pedro Ferreira^{3

4}, Volker Holzendorf⁵, Tobias D Trippel^{1

2}, Djawid Hashemi^{1

2}, Rolf Wachter^{6

7

8}, Christoph Herrmann-Lingen⁹, Gerd Hasenfuß^{6

7}, Faiez Zannad³, Burkert Pieske^{1

2

10

11}, Frank Edelmann^{1

2

7

11}

¹ Department of Internal Medicine and Cardiology, Charité University Medicine, Berlin, Germany.
² DZHK (German Centre for Cardiovascular Research), Berlin.
³ INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
⁴ Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.
⁵ Clinical Trial Centre Leipzig, University Leipzig, Leipzig, Germany.
⁶ Department of Cardiology and Pneumology, Georg-August University Goettingen, Goettingen, Germany.
⁷ DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.
⁸ Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany.
⁹ Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany.
¹⁰ Department of Cardiology, Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany.
¹¹ Berlin Institute of Health (BIH), Germany.

No abstract available

Publication types